GlassScriptPhysician profile
Chirag Patel
NPI 1891105474
$57,699.44
in general payments reported to CMS, 2019-2025
39 companies · $22K in 2025
The $22K reported for 2025 was more than what 92% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $81.74 · 2021: $967 · 2022: $12K · 2023: $2,634 · 2024: $20K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $8,630 · Travel and Lodging: $2,459 · Consulting Fee: $1,745 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,490.00 |
| Food and Beverage | $8,629.79 |
| Travel and Lodging | $2,458.51 |
| Consulting Fee | $1,744.52 |
| Education | $268.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $37,906.40 | 2020-2025 | Tezspire, Fasenra, Bevespi Aerosphere |
| Alk-Abello, INC | $9,686.96 | 2022 | |
| Genzyme Corporation | $2,606.31 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $976.33 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $896.80 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Novartis Pharmaceuticals Corporation | $663.94 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $599.04 | 2021-2025 | Cuvitru, Hyqvia, Eohilia |
| Amgen INC. | $589.96 | 2021-2025 | Tezspire |
| Abbvie INC. | $575.46 | 2022-2024 | |
| Grifols USA, LLC | $389.70 | 2022-2025 | Xembify |
| Pfizer INC. | $311.16 | 2019-2025 | |
| Genentech USA, INC. | $301.97 | 2019-2025 | Xolair |
| Csl Behring | $270.40 | 2023-2025 | Andembry, Haegarda, Hizentra |
| Leo Pharma INC. | $226.55 | 2022-2024 | Adbry |
| Incyte Corporation | $216.72 | 2021-2025 | Opzelura |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chirag Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.